RDY stock icon

Dr. Reddy's Laboratories
RDY

$79.36
1.04%

Market Cap: $13.2B

 

About: Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Employees: 27,048

0
Funds holding %
of 6,728 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

453% more call options, than puts

Call options by funds: $1.18M | Put options by funds: $213K

33% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 67

2% more capital invested

Capital invested by funds: $1.79B [Q1] → $1.83B (+$41.5M) [Q2]

0.23% less ownership

Funds ownership: 14.67% [Q1] → 14.44% (-0.23%) [Q2]

5% less funds holding

Funds holding: 227 [Q1] → 216 (-11) [Q2]

31% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 35

33% less funds holding in top 10

Funds holding in top 10: 6 [Q1] → 4 (-2) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$87
10%
upside
Avg. target
$87
10%
upside
High target
$87
10%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Barclays
Balaji Prasad
50% 1-year accuracy
18 / 36 met price target
10%upside
$87
Overweight
Maintained
30 Jul 2024

Financial journalist opinion